Improvement of Lung Function in a Scleroderma Patient Treated for 12 Months with Cyclofenil
- 18 January 1980
- journal article
- research article
- Published by Uppsala Medical Society in Upsala Journal of Medical Sciences
- Vol. 85 (1) , 67-73
- https://doi.org/10.3109/03009738009179173
Abstract
A 48 year old male scleroderma patient with typical impairment of respiratory function, including low vital capacity, low static lung compliance and low diffusing capacity for carbon monoxide, was treated with cyclofenil for one year. Assessment of lung function after 3, 6 and 12 months treatment showed marked improvement of vital capacity, increased physical working capacity, less hypoxia at maximum work, increase of static lung compliance and decrease of maximal transpulmonary pressure. Closing capacity decreased, and an increase in diffusing capacity for carbon monoxide was seen.This publication has 14 references indexed in Scilit:
- Respiratory function in systemic lupus erythematosus, scleroderma, and rheumatoid arthritis.Annals of the Rheumatic Diseases, 1973
- SEPARATION OF GROWTH INHIBITING POTENCY FROM OESTROGENICITY IN DIFFERENT WEAK OESTROGENIC DRUGS OF VARIOUS CHEMICAL STRUCTURESActa Endocrinologica, 1971
- Epidemiology of Systemic Sclerosis (Scleroderma)Annals of Internal Medicine, 1971
- Lung function and the response to exercise in systemic sclerosisThorax, 1969
- Tridimensional photographic reconstruction in a study of the pathogenesis of honeycomb lungThorax, 1967
- The Lungs in Systemic SclerosisDiseases of the Chest, 1965
- Improved technique for estimating pleural pressure from esophageal balloonsJournal of Applied Physiology, 1964
- Honeycomb Lungs and Malignant Pulmonary Adenomatosis in SclerodermaThorax, 1959
- A Standardized Breath Holding Technique for the Clinical Measurement of the Diffusing Capacity of the Lung for Carbon Monoxide 1Journal of Clinical Investigation, 1957
- SCLERODERMA: RELATION OF PULMONARY CHANGES TO ESOPHAGEAL DISEASEAnnals of Internal Medicine, 1954